Pegylation: a novel process for modifying pharmacokinetics.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2165/00003088-200140070-00005PMID 11510630
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer

  2012cited by this paper
• Liposomes

  2012cited by this paper
• Clinical Efficacy and Prospects for Use of Pegylated Liposomal Doxorubicin in the Treatment of Ovarian and Breast Cancers

  2012cited by this paper
• Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo.

  2009cited by this paper
• Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.

  2001cited by this paper
• Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C

  2001cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• A pharmacokinetic model for alpha interferon administered subcutaneously.

  1999cited by this paper
• Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

  1998cited by this paper
• Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.

  1998cited by this paper
• Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins.

  1998cited by this paper
• Polyethylene glycol-conjugated pharmaceutical proteins

  1998cited by this paper
• The interaction of liposomes with the complement system.

  1998cited by this paper
• Combined Use of Carboxyl-Directed Protein Pegylation and Vector-Mediated Blood-Brain Barrier Drug Delivery System Optimizes Brain Uptake of Brain-Derived Neurotrophic Factor Following Intravenous Administration

  1998cited by this paper
• Effect of the prokinetic agent, erythromycin, in the richardson ground squirrel model of cholesterol gallstone disease

  1998cited by this paper
• Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.

  1998cited by this paper
• Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

  1997cited by this paper
• Pegaspargase: An Alternative?

  1997cited by this paper
• Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.

  1997cited by this paper
• Preparation and Characterization of Poly(ethylene glycol)ylated Human Growth Hormone Antagonist

  1997cited by this paper
• Introduction to Chemistry and Biological Applications of Poly(ethylene glycol)

  1997cited by this paper
• PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency

  1997cited by this paper
• Biochemistry and Immunology of Poly(ethylene glycol)-Modified Adenosine Deaminase (PEG-ADA)

  1997cited by this paper
• Population pharmacokinetics and pharmacodynamics of pegylated‐liposomal doxorubicin in patients with AIDS‐related Kaposi's sarcoma

  1997cited by this paper
• Safety of Poly(ethylene glycol) and Poly(ethylene glycol) Derivatives

  1997cited by this paper
• Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

  1996cited by this paper
• Characterization and Stability of N-terminally PEGylated rhG-CSF

  1996cited by this paper
• Preparation of characterization of poly(ethylene glycol) vinyl sulfone.

  1996cited by this paper
• Polyethylene glycol modification: relevance of improved methodology to tumour targeting.

  1996cited by this paper
• Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa‐2a and a polyethylene glycol‐modified derivative in healthy subjects

  1996cited by this paper
• Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins.

  1996cited by this paper
• Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.

  1995cited by this paper
• Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol).

  1995cited by this paper
• A branched monomethoxypoly(ethylene glycol) for protein modification.

  1995cited by this paper
• PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.

  1995cited by this paper
• Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice.

  1995cited by this paper
• Novel Oral Drug Formulations

  1994cited by this paper
• Polymers for delivering peptides and proteins.

  1994cited by this paper
• Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice.

  1994cited by this paper
• Management options: SCIDS with adenosine deaminase deficiency.

  1994cited by this paper
• The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential

  1993cited by this paper
• L-asparaginase and PEG asparaginase--past, present, and future.

  1993cited by this paper
• The uses and properties of PEG-linked proteins.

  1992cited by this paper
• The Role of Pharmacokinetics in the Development of Biotechnologically Derived Agents

  1992cited by this paper
• The therapeutic value of poly(ethylene glycol)-modified proteins

  1991cited by this paper
• Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

  1988cited by this paper
• A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function.

  1985cited by this paper
• Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

  1984cited by this paper
• A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin.

  1983cited by this paper
• Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol.

  1981cited by this paper
• Enzyme-Polyethylene Glycol Adducts: Modified Enzymes with Unique Properties

  1978cited by this paper

• A Star-PEGylation Strategy to Improve Testosterone Pharmacokinetics

  2026cites this paper
• Effects of Liposome Composition and Size on Protein Corona Formation: Competitive Replacement of Abundant Proteins by High-Affinity Proteins on the Liposome Surface.

  2026cites this paper
• Nanotheranostics in Zebrafish Cancer Models: Insights into Targeting, Biodistribution, and Systemic Drug Delivery.

  2026cites this paper
• Charge Detection Mass Spectrometry and a Glu-C/Lys-C Digestion-Based Data-Dependent Approach Suggest Mono-PEGylation of a Heterogenous Therapeutic Protein.

  2026cites this paper
• Nano-formulated curcumin uptake and biodistribution in the fetal growth restricted newborn piglet brain

  2025cites this paper
• International consensuses and guidelines on managing ocular Behçet's disease by the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII), and the Academia Retina Internation

  2025cites this paper
• Exploratory Pharmacokinetic Study of Pegylated Interferon Alfa-2b Aerosolized Inhalation Administration.

  2025cites this paper
• Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery

  2025cites this paper
• Improved Ex‐Vivo Bond Quality Monitoring of Plasmonic Metal Oxide Biomaterials Mediated Laser Tissue Soldering Process Using Fast Noninvasive Optical Tomographic Imaging

  2025cites this paper
• Chemical catalyst manipulating cancer epigenome and transcription

  2025cites this paper
• Acoustic tweezers for targeted drug delivery.

  2025cites this paper
• Polycarboxybetaine in advanced drug delivery systems: From structure-function relationship to therapeutic applications

  2025cites this paper
• Developments in Ion Exchange Chromatography–Mass Spectrometry for the Characterization of Intact Proteins and Proteoforms

  2025cites this paper
• Nanotechnologies for targeted bacteriophage therapy: a review

  2025cites this paper
• Overcoming Biological Barriers in Cancer Therapy: Cell Membrane-Based Nanocarrier Strategies for Precision Delivery

  2025cites this paper
• Effectiveness of polyethylene glycol and glutaraldehyde as enhancers for lipase-immobilized hybrid organic–inorganic nanoflowers

  2025cites this paper
• Therapeutic Implications of Biomolecular Corona on Lipid Nanoparticle‐Based Gene Delivery Systems

  2025cites this paper
• New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024

  2025cites this paper
• Molecular Dynamics Simulations of Protein Corona Formation on Membrane Surfaces: Effects of Lipid Composition and PEGylation on Selective Plasma Protein Adsorption.

  2025cites this paper
• Targeted Drug Delivery to the Spleen and Its Implications for the Prevention and Treatment of Cancer

  2025cites this paper
• Breaking the oncogenic alliance: advances in disrupting the MTDH–SND1 complex for cancer therapy

  2025cites this paper
• The Influence of Protein Corona on Liposomal Delivery Systems: A Comprehensive Review.

  2025cites this paper
• Study of PEG-rhG-CSF for the prevention of neutropenia in concurrent chemoradiotherapy for nasopharyngeal carcinoma

  2025cites this paper
• The chimeric aptamer axl-miR-214sponge inhibits breast cancer and melanoma dissemination

  2025cites this paper
• Polymer Conjugation Benefits Proteins Beyond Simply Extended Half-life.

  2025cites this paper
• Melanin Nanoparticles as a Safe and Effective Iron Chelation Therapy: An ex vivo Assessment of Human Placental Transfer in Pregnant Beta-Thalassemia

  2025cites this paper
• Oral delivery of protein and peptide therapeutics.

  2025cites this paper
• Nanotechnology in medicine revolutionizing drug delivery for cancer and viral infection treatments.

  2024cites this paper
• Improving chemoradiotherapy strategy with PEGylated doxorubicin loaded gold nanoparticles against oral cancers

  2024cites this paper
• A Phosphoramidate Prodrug Platform: One-Pot Amine Functionalization of Kinase Inhibitors with Oligoethylene Glycol for Improved Water-Solubility.

  2024cites this paper
• A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research

  2024cites this paper
• Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis

  2024cites this paper
• Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)

  2024cites this paper
• Advances in cell membrane-based biomimetic nanodelivery systems for natural products

  2024cites this paper
• Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia

  2024cites this paper
• Unravelling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions.

  2024cites this paper
• Optimizing Pharmacological and Immunological Properties of Therapeutic Proteins Through PEGylation: Investigating Key Parameters and Their Impact

  2024cites this paper
• Roadmap for Clinical Translation of Mobile Microrobotics

  2024cites this paper
• Development of Polymethine Dyes for NIR‐II Fluorescence Imaging and Therapy

  2024cites this paper
• In vitro influence of PEG functionalized ZnO–CuO nanocomposites on bacterial growth

  2024cites this paper
• Doxorubicin-loaded PEG-CdTe QDs conjugated with anti-CXCR4 mAbs: a novel delivery system for extramedullary multiple myeloma treatment

  2024cites this paper
• Effects of Spherical and Rod-like Gold Nanoparticles on the Reactivity of Human Peripheral Blood Leukocytes

  2024cites this paper
• Engineering interferons for cancer immunotherapy.

  2024cites this paper
• Pegyliertes Interferon‐α2a bei kutanen T‐Zell‐Lymphomen – eine multizentrische retrospektive Datenanalyse mit 70 Patienten

  2024cites this paper
• Macrophage-mannose-receptor-targeted photoactivatable agent for in vivo imaging and treatment of atherosclerosis.

  2024cites this paper
• Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

  2024cites this paper
• Intact quantitation and evaluation of a PEG-glycosulfopeptide as a therapeutic P-selectin antagonist

  2024cites this paper
• Development of Hemoglobin-based Oxygen Delivery System Using PEGylation

  2024cites this paper
• Effect of PEGylation on the Adsorption and Binding Strength of Plasma Proteins to Nanoparticle Surfaces.

  2024cites this paper
• Synthesis, physicochemical characterization, and investigation of anti-inflammatory activity of water-soluble PEGylated 1,2,4-Triazoles.

  2024cites this paper
• Selective Transfection of a Transferrin Receptor-Expressing Cell Line with DNA–Lipid Nanoparticles

  2024cites this paper
• PEGylated lipid polymeric nanoparticles for management of rheumatoid arthritis

  2024cites this paper
• Clinical translation of wireless soft robotic medical devices

  2024cites this paper
• A Comprehensive Analysis of Biopharmaceutical Products Listed in the FDA’s Purple Book

  2024cites this paper
• Gold nanorod-based smart platform for efficient cellular uptake and combination therapy

  2024cites this paper
• Pegylated interferon‐α2a in cutaneous T‐cell lymphoma – a multicenter retrospective data analysis with 70 patients

  2024cites this paper
• Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle

  2024cites this paper
• Recent Advances in Simulation Studies on the Protein Corona

  2024cites this paper
• Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture.

  2023cites this paper
• Differences in protein distribution, conformation, and dynamics in hard and soft coronas: dependence on protein and particle electrostatics.

  2023cites this paper
• Virus-like particle-based nanocarriers as an emerging platform for drug delivery

  2023cites this paper
• Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice.

  2023cites this paper
• Direct Assessment of Oligomerization of Chemically Modified Peptides and Proteins in Formulations using DLS and DOSY-NMR

  2023cites this paper
• PEGylation, the Glorious Past, Present Dilemma and Future

  2023cites this paper
• Poly(oxanorbornene)-Protein Conjugates Prepared by Grafting-to Romp as Alternatives for Peg.

  2023cites this paper
• Lipidization as a tool toward peptide therapeutics

  2023influential citation
• PEGylation Strategy for Improving the Pharmacokinetic and Antitumoral Activity of the IL-2 No-alpha Mutein.

  2023cites this paper
• On the Mobility of Nanoparticles in Entangled Polymer Solutions

  2023cites this paper
• Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection

  2023cites this paper
• Treatment-induced and pre-existing anti-PEG antibodies: Prevalence, clinical implications, and future perspectives.

  2023cites this paper
• Tumor Abnormality-Oriented Nanomedicine Design.

  2023cites this paper
• Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme

  2023cites this paper
• Dual-Responsive Enzyme-Polysaccharide Conjugate as a Nanocarrier System for Enzyme Prodrug Therapy.

  2023cites this paper
• Polyethylene Glycol Induced Structural Modulation of Holo alpha-Lactalbumin: In vitro and In vivo Approach towards Protein Stability

  2023cites this paper
• Pulmonary Delivery for miRs: Present and Future Potential

  2023cites this paper
• Lipidation and PEGylation Strategies to Prolong the in Vivo Half-Life of a Nanomolar EphA4 Receptor Antagonist.

  2023cites this paper
• Pegylation – in search of balance and enhanced bioavailability

  2022cites this paper
• Hexapeptide decorated β-cyclodextrin delivery system for targeted therapy of bone infection.

  2022cites this paper
• Anti-platelet peptides targeting αIIbβ3 outside-in signaling pathway.

  2022cites this paper
• Developmental toxicity of nanomaterials used in drug delivery: understanding molecular biomechanics and potential remedial measures

  2022cites this paper
• Near-infrared spectroscopy: An important noninvasive and sensitive tool for point-of-care biosensing application

  2022cites this paper
• Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics

  2022cites this paper
• Biotherapeutics ADME and PK/PD Principles

  2022cites this paper
• Immunostimulant plant proteins: Potential candidates as vaccine adjuvants

  2022cites this paper
• Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes

  2022cites this paper
• Achievements and bottlenecks of PEGylation in nano-delivery systems.

  2022cites this paper
• A High-Affinity 64Cu-Labeled Ligand for PET Imaging of Hepsin: Design, Synthesis, and Characterization

  2022cites this paper
• Pegvisomant: uso clínico en pacientes con acromegalia

  2022cites this paper
• Derivatization with fatty acids in peptide and protein drug discovery

  2022cites this paper
• Chemical Conjugation in Drug Delivery Systems

  2022cites this paper
• Clinical application and future direction of liposomal assisted drug delivery system

  2022cites this paper
• New Nicotinic Acid-based Hydrogel: Swelling and Insulin Uptake Studies

  2022cites this paper
• Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects

  2022cites this paper
• Metal-Phenolic Networks as Versatile Coating Materials for Biomedical Applications.

  2022cites this paper
• Localization of Multi-Lamellar Vesicle Nanoparticles to Injured Brain Tissue in a Controlled Cortical Impact Injury Model of Traumatic Brain Injury in Rodents

  2022cites this paper
• Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations

  2022cites this paper
• Design of pH-responsive polymeric nanocarrier for targeted delivery of pyrogallol with enhanced antitumor potential in colon cancer.

  2022cites this paper
• Porous Silicon Nanoparticles Targeted to the Extracellular Matrix for Therapeutic Protein Delivery in Traumatic Brain Injury.

  2022cites this paper
• A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19–Recovered Patients as a Probable Therapy for COVID-19

  2021cites this paper
• Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems.

  2021cites this paper